| Market Capitalization (Millions $) |
2,638 |
| Shares
Outstanding (Millions) |
67 |
| Employees |
198 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-284 |
| Cash Flow (TTM) (Millions $) |
19 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development of innovative immunotherapies to treat various types of cancer and other difficult-to-treat diseases. The company's goal is to harness the power of the immune system to combat diseases by targeting specific proteins and pathways that play a role in disease progression.
Celldex Therapeutics has a diverse pipeline of product candidates, which includes novel monoclonal antibodies, antibody-drug conjugates, and vaccines. These candidates are designed to target and stimulate the immune system to recognize and destroy cancer cells, while also reducing the toxic side effects associated with traditional chemotherapy treatments.
One of the company's lead candidates is Glembatumumab Vedotin, an antibody-drug conjugate currently in clinical trials for the treatment of triple-negative breast cancer. Another promising candidate is CDX-1140, a fully human monoclonal antibody that activates the immune system's natural killer cells to fight against cancer.
Celldex Therapeutics has established collaborations with other pharmaceutical companies and research institutions to further advance their product candidates. They are committed to advancing scientific knowledge and improving patient outcomes through research and development of innovative immunotherapies.
Company Address: Perryville III Building Hampton 8827 NJ
Company Phone Number: 200-7500 Stock Exchange / Ticker: NASDAQ CLDX
|
1.35% 
100 %